CAR T treatment access and outcomes in patients with large B‐cell lymphoma according to ethnicity and socioeconomic deprivation.

However, patients from more deprived areas had inferior overall survival and access to post-CAR T therapies, underscoring healthcare inequalities in these patients. B Background: b CAR T-cell therapy has revolutionised treatment of relapsed/refractory (r/r) large B-cell lymphoma (LBCL), but it is unclear whether access and clinical benefit is equal for ethnic minorities and deprived communities. CAR T treatment access and outcomes in patients with large B-cell lymphoma according to ethnicity and socioeconomic deprivation. [Extracted from the article]